Suppr超能文献

头孢曲松介导合成的金纳米颗粒:一种靶向细菌耐药性的纳米治疗工具。

Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance.

作者信息

Alshammari Farhan, Alshammari Bushra, Moin Afrasim, Alamri Abdulwahab, Al Hagbani Turki, Alobaida Ahmed, Baker Abu, Khan Salman, Rizvi Syed Mohd Danish

机构信息

Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.

Department of Medical Surgical Nursing, College of Nursing, University of Ha'il, Ha'il 81442, Saudi Arabia.

出版信息

Pharmaceutics. 2021 Nov 8;13(11):1896. doi: 10.3390/pharmaceutics13111896.

Abstract

Ceftriaxone has been a part of therapeutic regime for combating some of the most aggressive bacterial infections in the last few decades. However, increasing bacterial resistance towards ceftriaxone and other third generation cephalosporin antibiotics has raised serious clinical concerns especially due to their misuse in the COVID-19 era. Advancement in nanotechnology has converted nano-therapeutic vision into a plausible reality with better targeting and reduced drug consumption. Thus, in the present study, gold nanoparticles (GNPs) were synthesized by using ceftriaxone antibiotic that acts as a reducing as well as capping agent. Ceftriaxone-loaded GNPs (CGNPs) were initially characterized by UV-visible spectroscopy, DLS, Zeta potential, Electron microscopy and FT-IR. However, a TEM micrograph showed a uniform size of 21 ± 1 nm for the synthesized CGNPs. Further, both (CGNPs) and pure ceftriaxone were examined for their efficacy against , and . CGNPs showed MIC as 1.39, 1.6, 1.1 and 0.9 µg/mL against , , and , respectively. Interestingly, CGNPs showed two times better efficacy when compared with pure ceftriaxone against the tested bacterial strains. Restoring the potential of unresponsive or less efficient ceftriaxone via gold nanoformulations is the most alluring concept of the whole study. Moreover, applicability of the findings from bench to bedside needs further validation.

摘要

在过去几十年里,头孢曲松一直是治疗某些最具侵袭性细菌感染的治疗方案的一部分。然而,细菌对头孢曲松和其他第三代头孢菌素抗生素的耐药性不断增加,引发了严重的临床担忧,尤其是在新冠疫情时代其被滥用的情况下。纳米技术的进步已将纳米治疗愿景转变为一个合理的现实,具有更好的靶向性和更低的药物消耗。因此,在本研究中,通过使用头孢曲松抗生素作为还原剂和封端剂来合成金纳米颗粒(GNPs)。负载头孢曲松的金纳米颗粒(CGNPs)最初通过紫外可见光谱、动态光散射、zeta电位、电子显微镜和傅里叶变换红外光谱进行表征。然而,透射电子显微镜图像显示合成的CGNPs尺寸均匀,为21±1纳米。此外,对(CGNPs)和纯头孢曲松针对[具体细菌名称缺失]、[具体细菌名称缺失]和[具体细菌名称缺失]的疗效进行了检测。CGNPs对[具体细菌名称缺失]、[具体细菌名称缺失]、[具体细菌名称缺失]和[具体细菌名称缺失]的最低抑菌浓度分别为1.39、1.6、1.1和0.9微克/毫升。有趣的是,与纯头孢曲松相比,CGNPs对测试的细菌菌株显示出两倍的疗效。通过金纳米制剂恢复无反应或效率较低的头孢曲松的潜力是整个研究中最具吸引力的概念。此外,从实验室到临床应用的研究结果还需要进一步验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331b/8622407/74b751782623/pharmaceutics-13-01896-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验